Stock Story -
Personal care company Nu Skin (NYSE:NUS) will be reporting earnings tomorrow after market close. Here's what investors should know.
Nu Skin missed analysts' revenue expectations by 3.5% last quarter, reporting revenues of $417.3 million, down 13.3% year on year. It was a slower quarter for the company, with full-year revenue guidance missing analysts' expectations and a miss of analysts' gross margin estimates.
Is Nu Skin a buy or sell going into earnings? Find out by reading the original article on StockStory, it's free.
This quarter, analysts are expecting Nu Skin's revenue to decline 13.7% year on year to $431.9 million, a further deceleration from the 10.8% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.17 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Nu Skin has missed Wall Street's revenue estimates six times over the last two years.
Looking at Nu Skin's peers in the personal care segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Edgewell Personal Care (NYSE:EPC) posted flat year-on-year revenue, meeting analysts' expectations, and Olaplex (NASDAQ:OLPX) reported a revenue decline of 4.8%, in line with consensus estimates.
Read the full analysis of Edgewell Personal Care's and Olaplex's results on StockStory.
There has been positive sentiment among investors in the personal care segment, with share prices up 3.4% on average over the last month. Nu Skin is up 4.8% during the same time and is heading into earnings with an average analyst price target of $12.8 (compared to the current share price of $10.24).
